MannKind Corporation (NASDAQ:MNKD) Releases Update On Afrezza® Prescribing Information

MannKind Corporation (NASDAQ:MNKD) reported that the U.S. Food & Drug Administration has approved a revision to the Afrezza prescribing information to constitute new clinical data that was showcased at the 76th Scientific Sessions of American Diabetes Association in June 2016. Afrezza inhalation powder is permitted by the FDA to enhance glycemic control in adults with […]

MannKind Corporation (NASDAQ:MNKD) And One Drop To Strike A Collaboration To Help Diabetes Patients

MannKind Corporation (NASDAQ:MNKD) made an announcement about its collaboration with One drop revealing that they were going to engage in a randomized controlled trial. This will be in a bid to investigate the use of Afrezza inhaled insulin. One Drop’s integrated digital diabetes care platform will also be scrutinized further in an effort to identify the […]

Patrick Mccauley To Serve As The New Chief Commercial Officer For MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) is today excited to announce that Patrick McCauley is joining its team of top executive officers. He will serve in the capacity of the company’s Chief Commercial Officer. This will see him lead the provider’s commercials operations. He starts working with immediately, something that will see the company tap from his expertise […]

MannKind Corporation (NASDAQ:MNKD) Draws Remaining Funds under Mann Group Loan Arrangement

MannKind Corporation (NASDAQ:MNKD) has announced serving Mann Group LLC with a funding request notification in regards to the terms of the Mann Group Loan Arrangement to draw the outstanding $30.1 million of the agreement. After receiving the funding, MannKind will use the $10.6 million proceeds for capital and pay off its interest accrued under the […]

MannKind Corporation (NASDAQ:MNKD) Engages Locust Walk To Spark Progress In Mannkind’s Non-Insulin Technosphere-Based Pipeline Candidates

MannKind Corporation (NASDAQ:MNKD), which happens to be a top end company that focuses on discovery, development and commercialization of therapeutic products has made the much awaited announcement. The provider’s board of directors has reached the decision to explore the financial and strategic alternatives for MannKind’s elaborate Technosphere-based pipeline candidates. This Technosphere platform is associated with […]

BIOMM SA And Mannkind Corporation (NASDAQ:MNKD) Collaborate In A Distribution Deal For Afrezza In Brazil

MannKind Corporation (NASDAQ:MNKD) and BIOMM SA today went ahead to make the much awaited announcement. They just made their entry into an agreement that will see them commercialize Afrezza® (insulin human) Inhalation Powder in Brazil. The supply and distribution agreement provides that Biomm will be entrusted with preparing as well as filing the necessary applications […]

Sanofi SA (ADR) (NYSE:SNY), MannKind (NASDAQ:MNKD) In Afrezza Licensing Deal

Boston, MA 08/11/2014 (wallstreetpr) – French drug company Sanofi SA (ADR) (NYSE:SNY) and MannKind Corporation (NASDAQ:MNKD) have entered a global collaboration that involves developing and marketing of the inhaled insulin therapy, Afrezza, targeting adults with types 1 and 2 of diabetes. Afrezza is billed as rapid-acting inhaled insulin, a new solution for diabetes patients that […]

MannKind Corporation (NASDAQ:MNKD): A Hope In Diabetic Therapy

Boston, MA 05/30/2014 (wallstreetpr) – MannKind Corporation (NASDAQ:MNKD) is currently focusing on the development of medicines for the diabetic patients and yet to report a profit as its products are in different pipeline stages. The available funds are mostly used to keep on investing in R&D. Recently, Afrezza the lead product of MannKind received positive results […]

MannKind Corporation (NASDAQ:MNKD) Announces Q1 Financial Results

Boston, MA 05/28/2014 (wallstreetpr) –  The leading organization MannKind Corporation (NASDAQ:MNKD) recently announced the financial results for the Q1 of the current year. The details of the financial results can be found in below stated points- Financial Results: The company managed to earn a significant profit in the first quarter, but with profit increased the […]

Market Recap: Calumet Specialty Products Partners, L.P (NASDAQ:CLMT), Gentherm Inc (NASDAQ:THRM), MannKind Corporation (NASDAQ:MNKD)

Boston, MA 05/20/2014 (wallstreetpr) – Calumet Specialty Products Partners, L.P (NASDAQ:CLMT) intends to spend $50 million for the improvement of its San Antonio refinery. It acquired the refinery in January 2013 from NuStar Energy L.P. (NYSE:NS) for $30 million. However, the plant has been riddled with almost frequent spills with the latest happening last Friday. […]

MannKind Corporation (NASDAQ:MNKD) Dull On Rival’s IPO Plans

Boston, MA 04/15/2014 (wallstreetpr) – MannKind Corporation (NASDAQ:MNKD) continued to slide on Monday as well after the news broke that a potential rival has filed for IPO. The share prices of the company came down by 1.87% to $6.29. IPO Filing By Dance Last week, MannKind’s potential competitor, Dance Biopharm has reportedly filed papers with […]

MannKind Corporation (NASDAQ:MNKD) Sinking Awaiting FDA Approval

 Boston, MA 04/11/2014 (wallstreetpr) – MannKind Corporation (NASDAQ:MNKD) shares continue to sink in the market awaiting FDA decision on its new product, Afrezza, which is expected to be reviewed on July 15, 2014. Afrezza has already won approval for type-1 and type-2 diabetes, there is huge optimism that the same will be achieved with the FDA. […]

Mannkind Corporation (NASDAQ:MNKD) Receives Favorable Votes From Advisory Panel Of The FDA For Its Diabetes Treatment

Boston, MA 04/03/2014 (wallstreetpr) – MannKind Corporation (NASDAQ:MNKD) moves a step ahead in getting its first product marketed as the drugmaker’s inhaled diabetes treatment wins the support of a U.S. advisory panel. Members of an advisory board of the U.S. Food and Drug Administration voted 13-1 for MannKind’s treatment for Type 1 diabetes and 14-0 for […]

MannKind Corporation (NASDAQ:MNKD): Rising From The Ashes

Boston, MA 04/02/2014 (wallstreetpr) – After facing a fall in the business MannKind Corporation (NASDAQ:MNKD) is all set to make the right decisions and rectify all it’s mistakes to be back in business. FDA Shows Concerns Over Afrezza The FDA has shown its concern over the MannKind Corporation (NASDAQ:MNKD) produced Afrezza. Reportedly they are having speculations […]

MannKind Corporation (NASDAQ:MNKD) Receives FDA Approval for Affreza

Boston, MA 04/02/2014 (wallstreetpr) – Valencia based, MannKind Corporation (NASDAQ:MNKD) has received majority approval from an FDA panel for the use of  Affreza, in the treatment of diabetes This is a major milestone for MannKind, which has been trying over the past two years to launch its first product into the market. MannKind’s share price has […]